Crispr Therapeutics Ag (CRSP)

CapEx to Revenue

30.66%

Quarterly · Period ending:

CRSP logo

CRSP CapEx to Revenue

Latest reported30.66%
CRSP Quarterly CapEx/Revenue (0.00% → 30.66%)
High-resolution chart · PNG

CRSP capex to revenue history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Crispr Therapeutics Ag CapEx to Revenue — Quarterly
Period endingCapEx to Revenue
30.6551%
34.5679%
59.838%
8.324%
13.1166%
23.815%
0.7257%
36.3787%
136.7505%
143.0556%
0.369%
0%
5.0786%
3.059%
103,183.3333%
6,401.0638%
6,094.9367%
8,623.5955%
71.1916%
11,261.0942%
3.1603%
3,477.2277%
1,686.2162%
3,731.7568%
8,193.1818%
1,905.0955%
1.2361%
1.1612%
683.6478%
334.4512%
869.5652%
123.4458%
48.0699%
40.8689%
0.6342%
125.4294%
37.1301%
121.5316%
9.727%
97.4177%
131.6981%
48.7395%
203.6437%
0%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.